Salarius Pharmaceuticals Regains Nasdaq Compliance
Recently, Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) confirmed that it has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement, having received notification on September 4, 2025. This achievement represents a significant milestone for the company as it works to meet all necessary Nasdaq continued listing standards.
Understanding Nasdaq Listings and Compliance
Being compliant with the Nasdaq requirements is crucial for Salarius, as it ensures their stock remains publicly traded and accessible to investors. By meeting the Minimum Bid Price Requirement, the company has taken a definitive step forward. However, as noted in their communications, Salarius must continue to adhere to other listing standards, including the Equity Standard Requirement, which they have until October 20, 2025, to meet.
Ongoing Monitoring by Nasdaq
In addition to regaining compliance, Salarius will be under the watchful eye of a Mandatory Panel Monitor for the next year. This monitoring ensures that the company maintains its compliance status. Should Salarius fall out of compliance during this period, the Nasdaq Listing Qualifications Staff would issue a delisting determination letter. At that point, Salarius would have the opportunity to request a hearing with the Nasdaq Hearings Panel to appeal that determination.
Strategic Merger with Decoy Therapeutics
The company also recently announced a decisive move towards growth by entering into a definitive merger agreement with Decoy Therapeutics, Inc. This preclinical biopharmaceutical company is at the forefront of developing innovative peptide conjugate therapeutics. The merger will establish Decoy Therapeutics as a wholly owned subsidiary of Salarius, strengthening its position in the growing biopharmaceutical market.
Values and Future Potential
Expected to yield substantial value-creating opportunities, the merger with Decoy Therapeutics focuses on leveraging its IMP3ACT platform. This platform enables rapid design and manufacturing of peptide therapeutics aimed at treating unmet medical needs in respiratory infections and gastrointestinal cancers. Together, the companies plan to explore various therapeutic avenues, including potential targets for Salarius' existing drug candidates.
Leadership and Future Developments
The leadership structure post-merger will feature Decoy’s Co-founders, including CEO Frederick “Rick” Pierce and Chief Scientific Officer Barbara Hibner. They will be joined by Salarius' Acting CEO and CFO Mark Rosenblum, ensuring a formidable team at the helm of the new entity.
Innovations in Drug Development
One of the immediate goals is to advance Decoy’s promising pan-coronavirus antiviral treatment towards filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). Additionally, Decoy plans to further develop its programs targeting influenza, COVID-19, respiratory syncytial virus (RSV), and gastrointestinal cancers, marking a significant advancement in addressing public health needs.
Advancements in Cancer Therapies
Alongside the merger plans, Salarius continues to work on its lead drug candidate, seclidemstat, which is undergoing evaluation as a potential treatment for hematologic cancers, such as myelodysplastic syndrome and chronic myelomonocytic leukemia. The ongoing Phase 1/2 clinical study at MD Anderson Cancer Center will provide crucial data on its efficacy and safety.
Research Partnerships and Innovation
Salarius has garnered financial support from various reputable sources to further its clinical trials, including grants aimed at treating Ewing sarcoma. Their innovative approach to cancer treatment through novel compounds such as SP-3164 highlights their commitment to developing effective cancer therapies.
Contact Information
For inquiries, please reach out to Alliance Advisors IR. Jody Cain is available at jcain@allianceadvisors.com or by phone at 310-691-7100.
Frequently Asked Questions
What is the recent compliance achievement by Salarius Pharmaceuticals?
Salarius Pharmaceuticals has regained compliance with Nasdaq’s Minimum Bid Price Requirement, allowing their stock to continue trading.
What is the significance of the merger with Decoy Therapeutics?
The merger will enhance Salarius' product pipeline by incorporating Decoy's innovative therapeutics aimed at treating unmet medical needs.
How will the merger affect Salarius' operational strategy?
The merger is expected to unlock value creation through enhanced development of peptide therapeutics and advancement of existing drug candidates.
What steps must Salarius take to remain compliant with Nasdaq?
Salarius must meet all continued listing standards, including the Equity Standard Requirement, which has a specified deadline for compliance.
What key innovations are being pursued by Salarius and Decoy?
Both companies are focused on developing advanced therapeutics for cancer and viral infections, with Salarius leading in hematologic cancer treatments.
